Exact Sciences (Exact Sciences) Risk Assessment

View and export this data going back to 2001. Start your Free Trial

What is Exact Sciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Exact Sciences is: High Risk: High uncertainty.

Competitive Comparison of Exact Sciences's Risk Assessment

For the Diagnostics & Research subindustry, Exact Sciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exact Sciences's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Exact Sciences's Risk Assessment falls into.

Exact Sciences (NAS:EXAS) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Exact Sciences Risk Assessment Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Sciences (Exact Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (NAS:EXAS) » Definitions » Risk Assessment

Comparable Companies

QGEN CRL MEDP NTRA RVTY RDNT SHC GH NEOG DGX TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

EXK:Germany

Address

5505 Endeavor Lane, Madison, WI, USA, 53719

Website

https://www.exactsciences.com

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.

Executives

Brian Baranick	officer: Gen. Mgr., Precision Oncology	441 CHARMANY DRIVE, MADISON WI 53719
Sarah Condella	officer: SVP, Human Resources	441 CHARMANY DRIVE, MADISON WI 53719
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Everett Cunningham	officer: Chief Commercial Officer	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeffrey Thomas Elliott	officer: Chief Financial Officer	5505 ENDEAVOR LANE, MADISON WI 53719
James Edward Doyle	director	5505 ENDEAVOR LANE, MADISON WI 53719
James Herriott	officer: General Counsel	5505 ENDEAVOR LANE, MADISON WI 53719
Katherine S Zanotti	director	431 E 9TH STREET, HINSDALE IL 60521
Jacob A Orville	officer: General Manager, New Ventures	5505 ENDEAVOR LANE, MADISON WI 53719
Kevin T Conroy	director, officer: Vice President	5505 ENDEAVOR LANE, MADISON WI 53719
D Scott Coward	officer: SVP and General Counsel	441 CHARMANY DRIVE, MADISON WI 53719
Paul J Clancy	director	C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Graham Peter Lidgard	officer: SVP, Chief Scientific Officer	5505 ENDEAVOR LANE, MADISON WI 53719
Michael S Wyzga	director	RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Torsten Hoof	officer: General Manager, International	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063